FocalTherics (NASDAQ:FOCL) Director David Horn Purchases 10,000 Shares

Key Points

• Insider buying: Director David Horn purchased 10,000 FOCL shares at an average price of $4.75, investing $47,500 and increasing his stake to 10,000 shares.
• Weak quarterly results: FocalTherics reported a quarterly loss of $0.39 per share, missing the $0.20 loss consensus estimate, while revenue totaled $13.20 million. Analysts expect a full-year loss of $0.78 per share.
• Mixed analyst outlook: Ratings range from Strong Buy to Sell, producing a consensus “Hold” rating and an average price target of $7.75 versus the stock’s recent price near $4.76.

FocalTherics (NASDAQ:FOCL - Get Free Report) Director David Horn acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the purchase, the director owned 10,000 shares in the company, valued at $47,500. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

FocalTherics Stock Performance

FOCL stock opened at $4.76 on Monday. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The firm has a market cap of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. The company has a 50-day simple moving average of $5.39.

FocalTherics (NASDAQ:FOCL - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million for the quarter. As a group, equities analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On FocalTherics

A number of large investors have recently modified their holdings of FOCL. SmartHarvest Portfolios LLC acquired a new stake in shares of FocalTherics in the 1st quarter valued at $38,000. Lido Advisors LLC acquired a new position in shares of FocalTherics during the first quarter worth $40,000. Kovack Advisors Inc. acquired a new position in shares of FocalTherics during the fourth quarter worth $53,000. Leonteq Securities AG purchased a new position in FocalTherics in the fourth quarter valued at $313,000. Finally, Flax Pond Capital LLC purchased a new position in FocalTherics in the fourth quarter valued at $2,623,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on FOCL shares. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Piper Sandler reiterated a "neutral" rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday. Wall Street Zen cut FocalTherics from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Mizuho set a $15.00 price target on FocalTherics and gave the stock an "outperform" rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source